Establishment of drug-resistant gastric cancer cell lines and their proteomic profile
Project/Area Number |
21591676
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
General surgery
|
Research Institution | Iwate Medical University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
IWAYA Takeshi 岩手医科大学, 医学部, 助教 (70405801)
WAKABAYASHI Go 岩手医科大学, 医学部, 教授 (50175064)
|
Project Period (FY) |
2009 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
Keywords | 薬剤耐性 / 胃癌 / シスプラチン / バイオチップ / 分子ネットワーク / プロテオミクス / 抗癌剤 / 細胞集団 / 癌幹細胞 / ストレス反応 / シグナル伝達 / 蛋白アレイ / 分子間作用 |
Research Abstract |
It is important to clarify the drug-resistant mechanism of cancer cells in the context of cancer chemotherapy. Advances on adjuvant chemotherapy after oncologically curative operation have prolonged the long-term disease-free and overall survival rates. However, approximately 30-40% cases still experience recurrence despite of adjuvant chemotherapy. In the present study, we established a drug-resistant gastric cancer cell line to clarify the drug-resistant mechanism. Pathways for DNA damage response were found disrupted in the resistant cell line. These results suggest that the resistant cell is unable to control cell cycle or apoptosis, which results in continuous proliferation.
|
Report
(4 results)
Research Products
(44 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] 抗癌剤感受性関連タンパクプロファイルによる術後補助化学療法効果予測マーカーの同定2011
Author(s)
西塚哲, 石田和茂, 上杉憲幸, 松尾鉄平, 高橋正統, 藤原久貴, 千葉丈広, 木村祐輔, 大塚幸喜, 新田浩幸, 柏葉匡寛, 肥田圭介, 佐々木章, 水野大, 菅井有, 若林剛
Organizer
第111回日本外科学会
Place of Presentation
東京
Year and Date
2011-05-26
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-